Effectiveness and Safety of Nadroparin Therapy in Preterm and Term Neonates with Venous Thromboembolism
Open Access
- 2 April 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (7) , 1483
Abstract
Introduction: Optimal neonatal nadroparin dosages to treat venous thromboembolism (VTE) are unknown. Objective: To evaluate therapeutic nadroparin dosages to reach therapeutic target ranges (TTR: 0.5–1.0 International Unit (IU)/mL) and the effectiveness and safety of nadroparin in neonatal VTE. Methods: Retrospective study including neonates with VTE on nadroparin in a tertiary center between 2007 and 2018. Two groups were distinguished: neonates before (group 1) and after (group 2) switch to higher starting dosages in 2014. Results: Sixty-one neonates (44 preterm, 17 term) with 64 VTEs were included. TTR was reached in 32/64 (50%) VTEs (group 1: 35.7%; group 2: 61.1%). Median nadroparin dosage to reach TTR was 197 (97.9–330.3) IU/kg/12 h. No therapy-related deaths occurred. Recurrent VTE developed in 6 (9.8%) neonates. Complete clot resolution was observed in 31/41 (75.6%) VTEs. TTR was reached in 58.1% VTEs with complete clot resolution. No major bleeding occurred. Non-major clinically relevant bleedings occurred in 3/64 (4.7%) VTEs, consisting of large hematomas due to the use of subcutaneous catheters. Conclusions: High nadroparin dosages are needed to reach TTR in neonates, which seem to be safe. Clot resolution may occur without reaching TTR. Subcutaneous catheters may cause important bleeding complications.Keywords
This publication has 36 references indexed in Scilit:
- Trends in Venous Thromboembolism-Related Hospitalizations, 1994–2009Pediatrics, 2012
- Antithrombotic Therapy in Neonates and ChildrenChest, 2012
- Management and Outcome in 32 Neonates with Thrombotic EventsInternational Journal of Pediatrics, 2011
- Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparinThrombosis and Haemostasis, 2010
- Treatment of deep venous thrombosis with low molecular weight heparin in pediatric cancer patients: safety and efficacyBlood Coagulation & Fibrinolysis, 2009
- Evaluation of enoxaparin dosing requirements in infants and childrenThrombosis and Haemostasis, 2009
- Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and childrenBritish Journal of Pharmacology, 2008
- Nadroparin Therapy in Pediatric Patients With Venous Thromboembolic DiseaseJournal of Pediatric Hematology/Oncology, 2008
- Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic eventsThrombosis and Haemostasis, 2005
- Compartment syndrome in an elbw infant receiving low-molecular-weight heparinsThe Journal of Pediatrics, 2004